Top

Current Osteoporosis Reports

Published in:

Open Access 01-08-2020 | Osteogenesis Imperfecta | Rare Bone Diseases (CB Langman and E Shore, Section Editors)

Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta

Authors: Cecilia Götherström, Lilian Walther-Jallow

Published in: Current Osteoporosis Reports | Issue 4/2020

Abstract

Purpose of Review

Osteogenesis imperfecta (OI) is a chronic disease with few treatment options available. The purpose of this review is to provide an overview on treating OI with mesenchymal stem cells (MSC).

Recent Findings

Off-the-shelf MSC have a good safety profile and exhibit multilineage differentiation potential and a low immunogenic profile and are easy to manufacture. Their ability to migrate, engraft, and differentiate into bone cells, and also to act via paracrine effects on the recipient’s tissues, makes MSC candidates as a clinical therapy for OI. Due to their high osteogenic potency, fetal MSC offer an even higher therapeutic potential in OI compared with MSC derived from adult sources. Preclinical and initial clinical data support the use of MSC in treating OI.

Summary

The characteristics of MSC make them of great interest in treating OI. MSC may be safely transplanted via intravenous administration and show potential positive clinical effects.

Thomas IH, DiMeglio LA. Advances in the classification and treatment of osteogenesis imperfecta. Curr Osteoporos Rep. 2016;14(1):1–9. https://doi.org/10.1007/s11914-016-0299-y.CrossRefPubMed

Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, Paepe A, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. https://doi.org/10.1038/nrdp.2017.52.CrossRefPubMed

Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, et al. Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res. 2016;31(12):2159–66. https://doi.org/10.1002/jbmr.2895.CrossRefPubMed

Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–16.CrossRef

Sillence DO, Horton WA, Rimoin DL. Morphologic studies in the skeletal dysplasias. Am J Pathol. 1979;96(3):813–70.PubMedPubMedCentral

Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377–85.CrossRef

Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007;39(3):359–65. https://doi.org/10.1038/ng1968.CrossRefPubMed

Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53(1):1–5. https://doi.org/10.1016/j.ejmg.2009.10.007.CrossRefPubMed

Constantino CS, Krzak JJ, Fial AV, Kruger KM, Rammer JR, Radmanovic K, et al. Effect of bisphosphonates on function and mobility among children with osteogenesis imperfecta: a systematic review. JBMR Plus. 2019;3(10):e10216. https://doi.org/10.1002/jbm4.10216.CrossRefPubMedPubMedCentral

10.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.CrossRef

11.

Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000;6(11):1282–6.CrossRef

12.

Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101(8):2999–3001.CrossRef

13.

Chan J, Waddington SN, O'Donoghue K, Kurata H, Guillot PV, Götherström C, et al. Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. Stem Cells. 2007;25(4):875–84. https://doi.org/10.1634/stemcells.2006-0694.CrossRefPubMed

14.

Guillot PV, Cook HT, Pusey CD, Fisk NM, Harten S, Moss J, et al. Transplantation of human fetal mesenchymal stem cells improves glomerulopathy in a collagen type I alpha 2-deficient mouse. J Pathol. 2008;214(5):627–36. https://doi.org/10.1002/path.2325.CrossRefPubMed

15.

Heldring N, Mager I, Wood MJ, Le Blanc K, Andaloussi SE. Therapeutic potential of multipotent mesenchymal stromal cells and their extracellular vesicles. Hum Gene Ther. 2015;26(8):506–17. https://doi.org/10.1089/hum.2015.072.CrossRefPubMed

16.

Colombini A, Perucca Orfei C, Kouroupis D, Ragni E, De Luca P, Vigan OM, et al. Mesenchymal stem cells in the treatment of articular cartilage degeneration: new biological insights for an old-timer cell. Cytotherapy. 2019. https://doi.org/10.1016/j.jcyt.2019.10.004.

17.

Sagar R, Walther-Jallow L, David AL, Götherström C, Westgren M. Fetal mesenchymal stromal cells: an opportunity for prenatal cellular therapy. Curr Stem Cell Rep. 2018;4(1):61–8. https://doi.org/10.1007/s40778-018-0118-8.CrossRefPubMedPubMedCentral

18.

Guillot PV, Götherström C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells. 2007;25(3):646–54. https://doi.org/10.1634/stemcells.2006-0208.CrossRefPubMed

19.

Zhang ZY, Teoh SH, Chong MS, Schantz JT, Fisk NM, Choolani MA, et al. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells. 2009;27(1):126–37. https://doi.org/10.1634/stemcells.2008-0456.CrossRefPubMed

20.

Chan J, O'Donoghue K, Gavina M, Torrente Y, Kennea N, Mehmet H, et al. Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. Stem Cells. 2006;24(8):1879–91. https://doi.org/10.1634/stemcells.2005-0564.CrossRefPubMed

21.

Chan J, O'Donoghue K, Kennea N, de la Fuente J, Kumar S, Morgan J, et al. Myogenic potential of fetal mesenchymal stem cells. Ann Acad Med Singapore. 2003;32(5 Suppl):S11–3.PubMed

22.

De Coppi P, Callegari A, Chiavegato A, Gasparotto L, Piccoli M, Taiani J, et al. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol. 2007;177(1):369–76. https://doi.org/10.1016/j.juro.2006.09.103.CrossRefPubMed

23.

Kennea NL, Waddington SN, Chan J, O'Donoghue K, Yeung D, Taylor DL, et al. Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. Cell Cycle. 2009;8(7):1069–79.CrossRef

24.

Guillot PV, De Bari C, Dell'Accio F, Kurata H, Polak J, Fisk NM. Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources. Differentiation. 2008;76(9):946–57. https://doi.org/10.1111/j.1432-0436.2008.00279.x.CrossRefPubMed

25.

Zhang ZY, Teoh SH, Chong MS, Lee ES, Tan LG, Mattar CN, et al. Neo-vascularization and bone formation mediated by fetal mesenchymal stem cell tissue-engineered bone grafts in critical-size femoral defects. Biomaterials. 2010. https://doi.org/10.1016/j.biomaterials.2009.09.078.

26.

Le Blanc K, Tammik L, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31(10):890–6.CrossRef

27.

Götherström C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol. 2004;190(1):239–45.CrossRef

28.

Götherström C, Lundqvist A, Duprez IR, Childs R, Berg L, le Blanc K. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy. 2011;13(3):269–78. https://doi.org/10.3109/14653249.2010.523077.CrossRefPubMed

29.

Götherström C, Ringden O, Westgren M, Tammik C, Le Blanc K. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant. 2003;32(3):265–72.CrossRef

30.

Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11–20.CrossRef

31.

Pereira RF, O'Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1998;95(3):1142–7.CrossRef

32.

Panaroni C, Gioia R, Lupi A, Besio R, Goldstein SA, Kreider J, et al. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood. 2009;114(2):459–68. https://doi.org/10.1182/blood-2008-12-195859.CrossRefPubMedPubMedCentral

33.

Guillot PV, Abass O, Bassett JH, Shefelbine SJ, Bou-Gharios G, Chan J, et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood. 2008;111(3):1717–25. https://doi.org/10.1182/blood-2007-08-105809.CrossRefPubMed

34.

Vanleene M, Saldanha Z, Cloyd KL, Jell G, Bou-Gharios G, Bassett JH, et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood. 2011;117(3):1053–60. https://doi.org/10.1182/blood-2010-05-287565.CrossRefPubMed

35.

Jones GN, Moschidou D, Abdulrazzak H, Kalirai BS, Vanleene M, Osatis S, et al. Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta. Stem Cells Dev. 2014;23(3):262–76. https://doi.org/10.1089/scd.2013.0132.CrossRefPubMed

36.

Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. https://doi.org/10.1371/journal.pone.0047559.CrossRefPubMedPubMedCentral

37.

•• Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829–48. https://doi.org/10.3727/096368915X689622. The paper summarizes the recent progress in the MSC therapy field.CrossRefPubMed

38.

•• Nitkin CR, Bonfield TL. Concise review: mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements. Stem Cells Transl Med. 2017;6(2):539–65. https://doi.org/10.5966/sctm.2015-0427. The paper summarizes the recent progress in the MSC therapy field in the pediatric population.CrossRefPubMed

39.

Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001;97(5):1227–31.CrossRef

40.

Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002;99(13):8932–7.CrossRef

41.

Le Blanc K, Götherström C, Ringden O, Hassan M, McMahon R, Horwitz E, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79(11):1607–14.CrossRef

42.

•• Götherström C, Westgren M, Shaw SW, Åström E, Biswas A, Byers PH, et al. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med. 2014;3(2):255–64. https://doi.org/10.5966/sctm.2013-0090. The paper describes the two first prenatal fetal MSC transplantations as treatment of OI, which resulted in donor cell engraftment in bone and potential clinical effects.CrossRefPubMed

Title: Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta
Authors: Cecilia Götherström
Lilian Walther-Jallow
Publication date: 01-08-2020
Publisher: Springer US
Keywords: Osteogenesis Imperfecta
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Current Osteoporosis Reports / Issue 4/2020
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-020-00594-3

ACC 2024 Congress

Springer Medicine

Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

The Impact of Exercise on Bone Health in Type 2 Diabetes Mellitus—a Systematic Review

Correction to: New Developments in Fracture Risk Assessment

Muscle, Bone, and Fat Crosstalk: the Biological Role of Myokines, Osteokines, and Adipokines

Polycomb Repressive Complex 2: a Dimmer Switch of Gene Regulation in Calvarial Bone Development

Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases

Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients’ Quality of Life